Association analysis between variants of the interleukin-1β and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 1 B, 2008, Pages 269-276

  Tadić, Andrea ^a   Rujescu, Dan ^b   Müller, Matthias J ^c   Kohnen, Ralf ^d   Stassen, Hans H ^e   Szegedi, Armin ^f   Dahmen, Norbert ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL GIESSEN   (Germany)

^d IMEREM   (Germany)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f Organon   (United States)

Author keywords

Antidepressive agents; Genetic polymorphisms; Interleukin 1 beta; Interleukin 1 receptor antagonist; Major depression; Treatment outcome

Indexed keywords

ANTIDEPRESSANT AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; MIRTAZAPINE; PAROXETINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DETERMINATION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHARMACOGENETICS; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; SURVIVAL TIME; VARIABLE NUMBER OF TANDEM REPEAT;

EID: 41549162842     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s2262     Document Type: Article

References (45)

1. Anisman H. 2004. Considering cytokine panels. Brain Behav Immun, 18:221-2.
2. Anisman H, Merali Z. 1999. Anhedonic and anxiogenic effects of cytokine exposure. Adv Exp Med Biol, 461:199-233.
3. Anisman H, Ravindran A, Griffiths J, et al. 1999. Endocrine and cytokine correlates of major depression and dysthytmia with typical or atypical features. Mol Psychiatry, 4:182-8.
4. Anttila SA, Leinonen EV. 2001. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev, 7:249-64.
5. Benkert O, Szegedi A, Kohnen R. 2000. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry, 61:656-63.
6. Brambilla F, Maggioni M. 1998. Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatr Scand, 97:309-13.
7. Castanon N, Medina C, Mormede C, et al. 2004. Chronic administration of tianeptine balances lipopolysaccharide-induced expression of cytokines in the spleen and hypothalamus of rats. Psychoneuroendocrinology, 29:778-90.
8. Castanon N, Leonard BE, Neveu PJ, et al. 2002. Effects of antidepressants on cytokine production and actions. Brain Behav Immun, 16:569-74.
9. di Giovine FS, Takhsh E, Blakemore Al, et al. 1992. Single base polymorphism at -511 in the human interleukin-1 beta gene (IL-1 beta). Hum Mol Genet, 1:450.
10. Dunn AJ, Wang J, Ando T. 1999. Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv Exp Med Biol, 461:117-27.
11. El-Omar EM, Carrington M, Chow WH, et al. 2000. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature, 404:398-402.
12. Hayley S, Poulter MO, Merali Z, et al. 2005. The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience, 135:659-78.
13. Hurme M, Santtila S. 1998.IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1β genes. Eur J Immunol, 28:2598-602.
14. Kaestner F, Hettich M, Peters M, et al. 2005. Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity. J Affect Disord, 87:305-11.
15. Kagaya A, Kugaya A, Takebayashi M, et al. 2001. Plasma concentrations of interleukin-1 beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan. Neuropsychobiology, 43:59-62.
16. Kast RE. 2003. Anti- and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating tumor necrosis factor-alpha levels. Gen Hosp Psychiatry, 25:495-6.
17. Kenis G, Maes M. 2002. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol, 5:401-12.
18. Kraus T, Haack M, Schuld A, et al. 2002. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry, 35:220-5.
19. Kubera M, Kenis G, Bosmans E, et al. 2000. Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Pol J Pharmacol, 52:237-41.
20. Levine J, Barak Y, Chengappa KN, et al. 1999. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology, 40:171-6.
21. Licinio J, Mastronardi C, Wong ML. 2007. Pharmacogenetics of neuroimmune interactions in human psychiatric disorders. Exp Physiol, 92:807-11.
22. Licinio J, Wong ML. 1999. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry, 4:317-27.
23. Linthorst AC, Flachskamm C, Müller-Preuss P, et al. 1995. Effect of bacterial endotoxin and interleukin-1 beta on hippocampal serotonergic neurotransmission, behavioral activity, and free corticosterone levels: an in vivo microdialysis study. J Neurosci, 15:2920-34.
24. Maier SF, Watkins LR. 1995. Intracerebroventricular interleukin-1 receptor antagonist blocks the enhancement of fear conditioning and interference with escape produced by inescapable shock. Brain Res, 695:279-82.
25. Mallinckrodt CH, Clark WS, David SR. 2001. Accounting for dropout bias using mixed-effects models. J Biopharm Stat, 11:9-21.
26. Mallinckrodt CH, Clark SW, Carroll RJ, et al. 2003. Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations. J Biopharm Stat, 13:179-90.
27. Merali Z, Lacosta S, Anisman H. 1997. Effects of interleukin-1 beta and mild stress on alterations of norepinephrine, dopamine and serotonin neurotransmission: a regional microdialysis study. Brain Res, 761:225-35.
28. Nicklin MJ, Weith A, Duff GW. 1994. A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics, 19:382-4.
29. Obuchowicz E, Kowalski J, Labuzek K, et al. 2006. Amitriptyline and nortriptyline inhibit interleukin-1 release by rat mixed glial and microglial cell cultures. In J Neuropsychopharmacol, 9:27-35.
30. Owen BM, Eccleston D, Ferrier IN, et al. 2001. Raised levels of plasma interleukin-1 beta in major and postviral depression. Acta Psychiatr Scand, 103:226-8.
31. Pociot F, Molvig J, Wogensen L, et al. 1992. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest, 22:396-402.
32. Raison CL, Capuron L, Miller AH. 2006. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol, 27:24-31.
33. Ramamoorthy S, Ramamoorthy JD, Prasad PD, et al. 1995. Regulation of the human serotonin transporter by interleukin-1 beta. Biochem Biophys Res Commun, 216:560-7.
34. Rothermundt M, Arolt V, Peters M, et al. 2001. Inflammatory markers in major depression and melancholia. J Affect Disord, 63:93-102.
35. Schiepers OJ, Wichers MC, Maes M. 2005. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry, 29:201-17.
36. Song C, Merali Z, Anisman H. 1999. Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment. Neuroscience, 88:823-36.
37. Suzuki E, Shintani F, Kanba S, et al. 1996. Induction of interleukin-1 beta and interleukin-1 receptor antagonist mRNA by chronic treatment with various psychotropics in widespread area of rat brain. Neurosci Lett, 215:201-4.
38. Szegedi A, Rujescu D, Tadić A, et al. 2005. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J, 5:49-53.
39. Tadić A, Rujescu D, Müller MJ, et al. 2007a. A monoamine oxidase B gene variant and short-term antidepressant treatment response. Prog Neuropsychopharmacol Biol Psychiatry, 31:1370-7.
40. Tadić A, Müller MJ, Rujescu. D, et al. 2007b. The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet B Neuropsychiatr Genet, 144:325-31.
41. Tarlow JK, Blakemore AI, Lennard A, et al. 1993. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet, 91:403-4.
42. Thomas AJ, Davis S, Morris C, et al. 2005. Increase in interleukin-1beta in late-life depression. Am J Psychiatry, 162:175-7.
43. Yirmiya R, Pollak Y, Barak O, et al. 2001. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology, 24:531-44.
44. Yu YW, Chen TJ, Hong CJ, et al. 2003. Association study of the interleukin-beta (C-511T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response. Neuropsychopharmacology, 28:1182-5.
45. Zhu CB, Blakely RD, Hewlett WA. 2006. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology, 31:2121-31.